Reversing cardiac hypertrophy and heart failure using a cardiac targeting peptide linked to miRNA106a
Cardiac Targeting Peptide (CTP) delivers, specifically to the heart, reversibly linked miRNA106a. MiRNA106a targets genes in various pathways known to cause heart failure when they are over/hyper activated returning their expression to normal levels. In vivo analyses using a mouse heart failure model resulted in reversal of heart failure parameters in 19/20 mice.
Authors
- Kaan Taskintuna
- Gerard P. Ahern (ORCID: https://orcid.org/0000-0001-5317-7262)
- Maliha Zahid (ORCID: https://orcid.org/0000-0002-2986-9557)
- Jack Lopuszynski (ORCID: https://orcid.org/0000-0002-8752-8822)
- Kyle Korolowicz (ORCID: https://orcid.org/0000-0003-1116-6500)
- Siqi Cai (ORCID: https://orcid.org/0000-0001-9211-5259)
- Ray Yurko
- G. Ian Gallicano (ORCID: https://orcid.org/0000-0001-8399-1556)
- Kazi Islam (ORCID: https://orcid.org/0000-0003-1457-2037)
- Hongkun Wang
- Ming Lü (ORCID: https://orcid.org/0009-0006-8786-0012)
- Claire Deng
- Bryn Schoonover
Institutions
- Mayo Clinic (US)
- Georgetown University (US)
- Georgetown University Medical Center (US)
- Media and Process Technology (United States) (US)
- Mayo Clinic in Arizona (US)
- Applied Biomathematics (United States) (US)
- Vince Lombardi Cancer Clinic (US)
- Mayo Clinic in Florida (US)
Publication Details
- Journal
- Clinical and Translational Medicine
- Published
- 2025-08-01
- DOI
- https://doi.org/10.1002/ctm2.70432
- Citations
- 2
- Primary Topic
- GDF15 and Related Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 3.34
Funders
- American Heart Association
- National Institutes of Health